January 7, 2025, Taipei—Lotus Pharmaceutical Co., Ltd. ("Lotus" or "the Company," Taiwan TWSE ticker: 1795), a multinational pharmaceutical company, today announced that it has consummated the acquisition of the trademark, marketing authorization, economic interest, and manufacturing processes of Alphachymotrypsine Choay® for Vietnam and Cambodia from the French pharmaceutical company Sanofi. The closing of the deal was completed earlier than the Company’s initial expectation, allowing Lotus to consolidate revenue from Alphachymotrypsine Choay® sales starting from Q1 of 2025. This marks a significant milestone in the Company's expansion in Southeast Asia.
Alphachymotrypsine Choay® (Chymotrypsine) is a well-established treatment prescribed for edema after trauma, surgery, or burnsKnown for its effective anti-inflammatory properties, Alphachymotrypsine Choay® accelerates the reabsorption of inflammatory edemas, as well as postoperative and post-traumatic hematomas and edemas. In 2023, the sales of Alphachymotrypsine Choay® in Vietnam and Cambodia exceeded US$22 million.
Petar Vazharov, Chief Executive Officer of Lotus, stated: “Closing Alphachymotrypsine Choay transaction in Vietnam is a significant achievement for Lotus, as it allows us to bring Alphachymotrypsine Choay® fully into our SEA portfolio and serve patients with an effective anti-inflammatory treatment. This milestone further strengthens our commitment to building scale in the Southeast Asia businesses.”
The acquisition of Alphachymotrypsine Choay® marks the second major milestone for Lotus in Southeast Asia, as the company aggressively pursues growth opportunities in the region. By acquiring strong brands and integrating them into its sales platforms, Lotus is advancing toward its goal of becoming a leading pharmaceutical player in the Asia-Pacific region.
About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on novel and generic drugs, providing better, safer, and more accessible medicines. With a top-tier R&D and manufacturing platform in Asia, Lotus has partnerships in major markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in Asia and the US, with a portfolio exceeding 250 commercial products. Lotus invests in a diverse portfolio of high-barrier oncology treatments, complex generics, 505(b)(2), and NCE drugs through internal R&D and licensing. It also strengthens its competitiveness with biosimilars, supported by strategic partners. Its infrastructure is certified by leading regulatory authorities, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com